【诺诚健华股价现涨超 4%】截至发稿,诺诚健华股价上涨 3.46%,报 10.16 港元,成交额 6681.65 万港元。中国国家药监局药品审评中心官网公示,诺诚健华申报的 1 类新药 ICP-248 片拟纳入突破性治疗品种,用于特定患者。该新药为诺诚健华研发的 BCL2 抑制剂。此外,诺诚健华近日公告,公司自主研发的核心产品宜诺凯获国家药监局批准,用于一线治疗相关患者。奥布替尼被列为相关诊疗指南...
Source Link【诺诚健华股价现涨超 4%】截至发稿,诺诚健华股价上涨 3.46%,报 10.16 港元,成交额 6681.65 万港元。中国国家药监局药品审评中心官网公示,诺诚健华申报的 1 类新药 ICP-248 片拟纳入突破性治疗品种,用于特定患者。该新药为诺诚健华研发的 BCL2 抑制剂。此外,诺诚健华近日公告,公司自主研发的核心产品宜诺凯获国家药监局批准,用于一线治疗相关患者。奥布替尼被列为相关诊疗指南...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.